These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 6718635)

  • 1. Apomorphine and schizophrenia.
    Johns CA; Levy MI; Davis BM; Mohs RC; Kendler KS; Mathe AA; Trigos G; Horvath TB; Davis KL
    Psychopharmacol Bull; 1984; 20(1):103-7. PubMed ID: 6718635
    [No Abstract]   [Full Text] [Related]  

  • 2. [Apomorphine in dyskinesia and psychomotor agitation].
    Stoliarov GV; Markova OF
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1982; 82(8):97-102. PubMed ID: 7136384
    [No Abstract]   [Full Text] [Related]  

  • 3. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
    Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL
    Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia.
    Yamada K; Kanba S; Ohnishi K; Ashikari I; Yagi G; Asai M
    Biol Psychiatry; 1997 May; 41(10):1062-4. PubMed ID: 9129786
    [No Abstract]   [Full Text] [Related]  

  • 5. Low-dose apomorphine and bromocriptine in neuroleptic-induced movement disorders.
    Jeste DV; Cutler NR; Kaufmann CA; Karoum F
    Biol Psychiatry; 1983 Sep; 18(9):1085-91. PubMed ID: 6640005
    [No Abstract]   [Full Text] [Related]  

  • 6. Apomorphine and diphasic dyskinesia.
    Durif F; Deffond D; Dordain G; Tournilhac M
    Clin Neuropharmacol; 1994 Feb; 17(1):99-102. PubMed ID: 8149366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of intravenous and subcutaneous administration of apomorphine on the clinical symptoms of chronic schizophrenics.
    Syvälahti EK; Säkö E; Scheinin M; Pihlajamäki K; Hietala J
    Br J Psychiatry; 1986 Feb; 148():204-8. PubMed ID: 3516291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of dopamine agonists in the treatment of schizophrenia.
    Corsini GU; Pitzalis GF; Bernardi F; Bocchetta A; Del Zompo M
    Neuropharmacology; 1981 Dec; 20(12B):1309-13. PubMed ID: 7033816
    [No Abstract]   [Full Text] [Related]  

  • 9. [Biological methods of predicting the effectiveness of psychopharmacologic treatment of schizophrenia (review)].
    Nemtsov AV; Kalinin VV
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1981; 81(8):1232-41. PubMed ID: 6171962
    [No Abstract]   [Full Text] [Related]  

  • 10. Apomorphine in schizophrenia.
    Hollister LE; Davis KL; Berger PA
    Commun Psychopharmacol; 1980; 4(4):277-81. PubMed ID: 6115735
    [No Abstract]   [Full Text] [Related]  

  • 11. A case of tardive tremor successfully treated with clozapine.
    Delecluse F; Elosegi JA; Gérard JM
    Mov Disord; 1998 Sep; 13(5):846-7. PubMed ID: 9756158
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of sodium valproate and baclofen in tardive dyskinesia: clinical and neuroendocrine studies.
    Nair NP; Lal S; Schwartz G; Thavundayil JX
    Adv Biochem Psychopharmacol; 1980; 24():437-41. PubMed ID: 6773303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysphagia: a rare form of dyskinesia?
    Nieves JE; Stack KM; Harrison ME; Gorman JM
    J Psychiatr Pract; 2007 May; 13(3):199-201. PubMed ID: 17522565
    [No Abstract]   [Full Text] [Related]  

  • 14. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study.
    Miyaoka T; Furuya M; Yasuda H; Hayashida M; Nishida A; Inagaki T; Horiguchi J
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):761-4. PubMed ID: 18201810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apomorphine reduces schizophrenic symptoms.
    Schaffer MH; Tamminga CA; Smith RC; Davis JM
    Psychopharmacol Bull; 1980 Jan; 16(1):55-7. PubMed ID: 6987694
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial.
    Lee JG; Shin BS; Lee YC; Park SW; Kim YH
    Psychiatry Clin Neurosci; 2007 Oct; 61(5):509-14. PubMed ID: 17875029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schizophrenia and severe tardive dyskinesia responsive to risperidone.
    Kopala LC; Honer WG
    J Clin Psychopharmacol; 1994 Dec; 14(6):430-1. PubMed ID: 7533794
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of clozapine-associated tardive dyskinesia.
    Lin CC; Bai YM; Chen JY; Wang YC; Liou YJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):599-600. PubMed ID: 17920744
    [No Abstract]   [Full Text] [Related]  

  • 19. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effects of apomorphine in schizophrenia.
    Ferrier IN; Johnstone EC; Crow TJ
    Br J Psychiatry; 1984 Apr; 144():341-8. PubMed ID: 6372924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.